OnKure Therapeutics (OKUR) Current Assets (2020 - 2026)
OnKure Therapeutics' (OKUR) quarterly Current Assets came in at $197.5 million in Q1 2026, up 101.16% YoY from $98.2 million in Q1 2025, and up 224.6% on a QoQ basis from $60.8 million in Q4 2025.
OnKure Therapeutics (OKUR) Current Assets (2020 - 2026) Analysis & Trends
OnKure Therapeutics (OKUR) has 7 years of Current Assets data on file, last reported at $197.5 million in Q1 2026.
- Quarterly Current Assets rose 101.16% year-over-year to $197.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $197.5 million (up 101.16% YoY) and the FY2025 annual result came in at $60.8 million, down 46.16% from the prior year.
- Current Assets advanced to $197.5 million in Q1 2026, from $60.8 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $197.5 million in Q1 2026 to a low of $33.8 million in Q4 2023.
- A 5-year average of $104.3 million and a median of $98.2 million in 2025 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2023 — Current Assets tumbled 68.25% — and 2024, when it surged 234.67%.
- Tracing OKUR's Current Assets over 5 years: stood at $106.4 million in 2022, then plunged by 68.25% to $33.8 million in 2023, then surged by 234.67% to $113.0 million in 2024, then tumbled by 46.16% to $60.8 million in 2025, then jumped by 224.6% to $197.5 million in 2026.
- The last three Current Assets figures came in at $197.5 million (Q1 2026), $60.8 million (Q4 2025), and $71.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - | 1.76 Bn |
| 10 | OnKure Therapeutics | 199.48 Mn | 23.09 Mn | - | 177.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 177.68 Mn |
| Mar 31, 2026 | 197.48 Mn |
| Dec 31, 2025 | 60.84 Mn |
| Sep 30, 2025 | 71.53 Mn |
| Jun 30, 2025 | 84.55 Mn |
| Mar 31, 2025 | 98.17 Mn |
| Dec 31, 2024 | 113.00 Mn |
| Sep 30, 2024 | 77.00 Mn |
| Jun 30, 2024 | 77.99 Mn |
| Mar 31, 2024 | 83.93 Mn |
| Dec 31, 2023 | 33.77 Mn |
| Sep 30, 2023 | 128.77 Mn |
| Jun 30, 2023 | 146.32 Mn |
| Mar 31, 2023 | 97.02 Mn |
| Dec 31, 2022 | 106.35 Mn |
| Sep 30, 2022 | 121.00 Mn |
| Jun 30, 2022 | 132.01 Mn |
| Mar 31, 2022 | 142.72 Mn |
| Dec 31, 2021 | 153.73 Mn |
| Sep 30, 2021 | 162.67 Mn |